For the quarter ending 2025-09-30, FENCF had -$4,687K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net (loss)/income | -4,954 |
| Inventory reserve | -517 |
| Allowance for credit losses | 67 |
| Amortization of debt discount | 38 |
| Loss on securities | 2 |
| Amortization of norgine asset | 77 |
| Stock-based compensation - employees | 4,511 |
| Accounts receivable | 8,982 |
| Prepaid expenses | -1,681 |
| Inventory | 1,417 |
| Other assets | -85 |
| Accounts payable | 2,625 |
| Accrued liabilities | 273 |
| Net cash (used in) / provided by operating activities | -6,511 |
| Issuance of shares, options exercise | 1,985 |
| Cash paid for taxes on restricted share release | 161 |
| Net cash provided by / (used in) financing activities | 1,824 |
| (decrease) / increase in cash and cash equivalents | -4,687 |
| Cash and cash equivalents at beginning of period | 26,634 |
| Cash and cash equivalents at end of period | 21,947 |
FENNEC PHARMACEUTICALS INC. (FENCF)
FENNEC PHARMACEUTICALS INC. (FENCF)